Paediatric-onset multiple sclerosis before the age of 18 years, although uncommon, is associated with a higher disease burden than adult onset MS, early and progressive motor and cognitive disability, and high levels of depression and fatigue. In this episode Ann Yeh, Professor of Paediatrics and neurologist in Toronto, Canada, highlights the global considerations in preventing MS disease progression in young people with MS, including achieving global equity in access to diagnostics, specialist services, and highly-effective disease modifying therapies for adolescents and young adults with MS.

Read the Review in this month's issue here:

https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00133-6/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanchi

Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(24)00047-6/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanchi

Real-life benefits of high-efficacy therapies for children with multiple sclerosis https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(24)00074-9/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanchi

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://www.linkedin.com/company/lanchi/
https://youtube.com/thelancettv